A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer

LESSONS LEARNED. Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com). DHP107 i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Kim, Tae Won, Kim, Sung Bae, Lim, Hyeong‐Seok, Bae, Kyun‐Seop, Park, Sook Ryun, Jo, Yeong‐Woo, Cho, Hyun Ju, Kang, Yoon‐Koo
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330712/
https://ncbi.nlm.nih.gov/pubmed/28196905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0273
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares